1
|
Kolawole OM, Tomori O, Agbonlahor D, Ekanem E, Bakare R, Abdulsalam N, Okojie O, Braide E, Uzochukwu B, Rafindadi A, Bello S, Shehu S, Gureje O, Lecky M, Onwujekwe O, Onyedum C, Ezike A, Bukbuk D, Ashir G, Anyaehie B, Amazigo U, Habib A, Ufere J, Azodoh N. SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria. JAMA Netw Open 2022; 5:e2236053. [PMID: 36219441 PMCID: PMC9554701 DOI: 10.1001/jamanetworkopen.2022.36053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
IMPORTANCE The global impact of COVID-19 has led to an increased need to continuously assess disease surveillance tools. The utility of SARS-CoV-2 serologic tools in determining immunity levels across different age groups and locations in helping to quickly assess the burden of COVID-19 with significant health policy implications is unknown. OBJECTIVE To determine the prevalence of SARS-CoV-2 antibodies with respect to the age group and sex of participants. DESIGN, SETTING, AND PARTICIPANTS A cross-sectional survey of 4904 individuals across 12 states with high and low COVID-19 disease burden in Nigeria was carried out between June 29 and August 21, 2021. MAIN OUTCOMES AND MEASURES Enzyme-linked immunosorbent assay was used for the detection of specific SARS-CoV-2 immunoglobulin G and immunoglobulin M antibodies, such as the nucleocapsid protein-NCP and spike protein S1. Interviewer-administered questionnaires provided information on participants' history of disease and associated risk factors. RESULTS A total of 4904 individuals participated in the study (3033 were female [61.8%]; mean [SD] age, 26.7 [6.51] years). A high seroprevalence of SARS-CoV-2 (78.9%) was obtained. Seropositivity was consistent across the states surveyed, ranging from 69.8% in Lagos to 87.7% in Borno. There was no association between sex and seropositivity (female, 2414 [79.6%]; male, 1456 [77.8%]; P = .61); however, an association was noted between age and seropositivity, with the peak prevalence observed in participants aged 15 to 19 years (616 [83.6%]; P = .001). Similarly, loss of appetite (751 [82.3%]; P = .04) and smell (309 [84.4%]; P = .01) were associated with seropositivity. CONCLUSIONS AND RELEVANCE In this cross-sectional study, a high SARS-CoV-2 seroprevalence was obtained among the study population during the low level of vaccination at the time of the survey. Thus, there is a need for both an efficacy and antibody neutralization test study to ascertain the efficacy of the antibody detected and the potential for herd immunity in Nigeria.
Collapse
Affiliation(s)
- Olatunji Matthew Kolawole
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Oyewale Tomori
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Dennis Agbonlahor
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Ekanem Ekanem
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Rasheed Bakare
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Nasidi Abdulsalam
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Obehi Okojie
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Eka Braide
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Benjamin Uzochukwu
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Abdulmumini Rafindadi
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Shaibu Bello
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Sule Shehu
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Oye Gureje
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Muhammed Lecky
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Obinna Onwujekwe
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Cajetan Onyedum
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Adaobi Ezike
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - David Bukbuk
- Department of Microbiology, Faculty of Science, University of Maiduguri Teaching Hospital, Maiduguri, Borno State, Nigeria
| | - Garba Ashir
- Department of Microbiology, Faculty of Science, University of Maiduguri Teaching Hospital, Maiduguri, Borno State, Nigeria
| | - Bond Anyaehie
- Department of Physiology, College of Medicine, University of Nigeria, Enugu
| | - Uche Amazigo
- Pan-African Community Initiative on Education and Health, Enugu, Enugu State, Nigeria
| | - Abdulrajak Habib
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| | - Joy Ufere
- World Health Organization Country Office, Federal Capital Territory, Abuja, Nigeria
| | - Ngozi Azodoh
- Ministerial Expert Advisory Committee on COVID-19-Health Sector Response, Federal Ministry of Health, Abuja, Nigeria
| |
Collapse
|